Jun. 17 at 5:18 AM
$CPHI Today, CPHI saw massive volume — the most in 6 months. Over 1 million shares traded, which is huge considering CPHI has only about a 1.2M float and 64% insider ownership. Another Chinese drug company with heavy insider ownership,
$RGC was up over 300% today.
I believe that for a stock to move, we need three things: timing, narrative (company + products), and serious catalysts.
So why the sudden surge in CPHI volume? An article titled "US pharma bets big on China to snap up potential blockbuster drugs" circulated across mainstream outlets all day. Then after hours, this dropped: "China proposes shorter clinical trial reviews to accelerate drug development," through the NMPA, China's FDA. After reading these, I’m convinced that CPHI has all three ingredients that move a stock forward.
The article also noted that
$PFE struck a 1.25B deal with China’s 3SBio for a drug that could challenge Keytruda of
$MRK and
$LLY signed a 2B deal with a Chinese pharma for a GLP-1 obesity candidate.
